|
|
||||||||
1 Laboratory of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Aobayama, Sendai 980-8578; and 2 Department of Dental Pharmacology, The Nippon Dental University School of Dentistry at Niigata, Hamaura-cho, Niigata 951-8580, Japan
We elucidated the contribution of endogenous pituitary adenylate cyclase-activating polypeptide (PACAP) to neurally evoked catecholamine secretion from the isolated perfused rat adrenal gland. Infusion of PACAP (100 nM) increased adrenal epinephrine and norepinephrine output. The PACAP-induced catecholamine output responses were inhibited by the PACAP type I receptor antagonist PACAP- (6-38) (30-3,000 nM) but were resistant to the PACAP type II receptor antagonist [Lys1,Pro2,5,Ara3,4,Tyr6]-vasoactive intestinal peptide (LPAT-VIP; 30-3,000 nM). Transmural electrical stimulation (ES; 1-10 Hz) or infusion of ACh (6-200 nM) increased adrenal epinephrine and norepinephrine output. PACAP-(6-38) (3,000 nM), but not LPAT-VIP, also inhibited the ES-induced catecholamine output responses. However, PACAP-(6-38) did not affect the ACh-induced catecholamine output responses. PACAP at low concentrations (0.3-3 nM), which had no influence on catecholamine output, enhanced the ACh-induced catecholamine output responses, but not the ES-induced catecholamine output responses. These results suggest that PACAP is released from the nerve endings to facilitate the neurally evoked catecholamine secretion through PACAP type I receptors in the rat adrenal gland.
transmural electrical stimulation; acetylcholine; pituitary adenylate cyclase-activating polypeptide receptor antagonists; pituitary adenylate cyclase-activating polypeptide -(6-38); adrenal chromaffin cells
This article has been cited by other articles:
![]() |
O. Skott Pituitary adenylate cyclase-activating polypeptide and adrenomedullary function Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R586 - R587. [Full Text] [PDF] |
||||
![]() |
S. Lamouche and N. Yamaguchi PACAP release from the canine adrenal gland in vivo: its functional role in severe hypotension Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R588 - R597. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Morita, A. Sakakibara, S. Kitayama, K. Kumagai, K. Tanne, and T. Dohi Pituitary Adenylate Cyclase-Activating Polypeptide Induces a Sustained Increase in Intracellular Free Ca2+ Concentration and Catecholamine Release by Activating Ca2+ Influx via Receptor-Stimulated Ca2+ Entry, Independent of Store-Operated Ca2+ Channels, and Voltage-Dependent Ca2+ Channels in Bovine Adrenal Medullary Chromaffin Cells J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 972 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hamelink, O. Tjurmina, R. Damadzic, W. S. Young, E. Weihe, H.-W. Lee, and L. E. Eiden Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis PNAS, January 8, 2002; 99(1): 461 - 466. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |